menu
    • menu

    Company profile for Minoryx Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Minoryx is a clinical stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program, a differentiated PPAR gamma agonist (MIN-102), is a candidate for X-linked Adrenoleukodystrophy that has successfully completed phase 1 clinical trials and is now in a pivotal phase 2/3 trial.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Minoryx TherapeuticsSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    TCM3 Av. Ernest Lluch 32 · 08302 Mataró (Barcelona)
    Telephone
    Telephone
    +34 93 544 14 66
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.minoryx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Leriglitazone Meet Endpoint in Nexus Trial for Adrenoleukodystrophy
    Leriglitazone Meet Endpoint in Nexus Trial for Adrenoleukodystrophy

    11 Dec 2024

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2024-12-11/leriglitazone-has-met-the-primary-endpoint-in-nexus-the-pivotal-trial-for-pediatric-patients-with-cerebral-adrenoleukodystrophy

    PHARMAWEB
    11 Dec 2024
    Share Share
    Minoryx knocked back by EMA but vows to seek rerun of review
    Minoryx knocked back by EMA but vows to seek rerun of review

    26 Jan 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/minoryx-clutching-data-failed-trial-knocked-back-ema-vows-seek-rerun-review

    FIERCE BIOTECH
    26 Jan 2024
    Share Share
    FDA grants clearance to Minoryx for Phase III trial of cALD therapy
    FDA grants clearance to Minoryx for Phase III trial of cALD therapy

    01 Jun 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/fda-minoryx-phase-iii-trial-cald-therapy/

    CLINICAL TRIALS ARENA
    01 Jun 2023
    Share Share
    Minoryx and Neuraxpharm team to provide new therapy for rare CNS disorders
    Minoryx and Neuraxpharm team to provide new therapy for rare CNS disorders

    10 Nov 2022

    // EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/176282/minoryx-and-neuraxpharm-therapy-for-rare-cns-disorders/

    EUROPEANPHARMACEUTICALREVIEW
    10 Nov 2022
    Share Share
    Minoryx‘s marketing authorization application for lead candidate leriglitazone
    Minoryx‘s marketing authorization application for lead candidate leriglitazone

    20 Sep 2022

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2022-09-20/minoryx-s-marketing-authorization-application-for-its-lead-candidate-leriglitazone-validated-by-ema-for-orphan-indication-x-linked-adrenoleukodystrophy-x-ald

    PHARMIWEB
    20 Sep 2022
    Share Share
    Minoryx pockets €51M to guide rare disease drug to market
    Minoryx pockets €51M to guide rare disease drug to market

    31 May 2022

    // Nick Paul Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/bouncing-back-late-phase-fail-minoryx-pockets-eu51m-guide-rare-disease-drug-market

    Nick Paul Taylor FIERCEBIOTECH
    31 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search